| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() High-Dose Donepezil Slows Symptom Progression in Advanced Alzheimer's Disease: Presented at ADI By Jenny Powers THESSALONIKI, Greece -- March 13, 2010 -- According to the data presented here on March 11 at the 25th Conference of Alzheimer’s Disease International (ADI), patients with advanced Alzheimer’s disease (AD) and dementia were observed to have stronger symptom improvement with a higher dose of donepezil. Patients (mean age, 78.4 years) also demonstrated significantly increased cerebral blood flow following dose increase. The current treatment for patients with advanced AD and dementia in Japan is donepezil 5 mg. For the study, Kinoshi Kanaya, MD, Department of Geriatric Medicine, Tokyo Medical University, and Hachioji Medical Center, Tokyo, Japan, and colleagues assessed the efficacy of donepezil 10 mg daily in patients whose symptoms of dementia were progressing with donepezil 5 mg. Of the 24 patients available for analysis, 31.2% demonstrated increased cognitive function -- assessed by the Mini-Mental State Examination and the Alzheimer’s Disease Assessment Scale-cognitive subscale -- and 31.5% showed no change (no deterioration) in cognitive function. An increase in symptoms was seen in 31.3% (P = .05) of treated patients. The researchers also administered technetium-99m-ethyl cysteinate diethyl ester single photon emission computed tomography imaging twice after administration of donepezil 10 mg. A total of 20 patients (83.3%) demonstrated increased cerebral blood flow specifically in the bilateral temporal, occipital, and parietal lobes (P = .05). One patient was withdrawn from the study due to adverse effects involving gastrointestinal symptoms. However, the treatment was generally well tolerated. [Presentation title: Usefulness of Administration of 10 mg/Day Dosage Donepezil Hydrochloride (Aricept) to Dementia Alzheimer’s Type (DAT) - Comparative Study With 5 Mg By Neuropsychological Testing and SPECT Imaging. Abstract P002]
|